A phase I/II trial of escalating doses of recombinant human keratinocyte growth factor (rHuKGF) in head & neck cancer (HNC) patients receiving radiotherapy (RT) with concurrent chemotherapy (CCT)
David M. Brizel(Duke University), Bin Yao(Puma Biotechnology (United States)), Don R. Goffinet(Stanford Cancer Institute), V.M. Venkatesan, Sanjiv S. Agarwala(Goethe University Frankfurt), C. Cripps(Canadian Partnership Against Cancer), Ruby F. Meredith(University of Nebraska Medical Center), Terence S. Herman(University of Debrecen), Gary N. Schwartz(Roswell Park Comprehensive Cancer Center), Scott L. Sailer(Waverly Hematology Oncology), Eileen Logan(Amgen (United States))
International Journal of Radiation Oncology*Biology*Physics
November 1, 2001
Cited by 22
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
|Journal of Clinical Oncology|1999|763